Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korea's Economy Minister Pledges Support For Local Biosimilar Companies

This article was originally published in The Pink Sheet Daily

Executive Summary

Ministry will invest about $7.5 million by July 2010 in a consortium headed by Samsung Electronics and antibody company ISU Abxis to manufacture nine biosimilar products after their patents expire.

You may also be interested in...



Korea's Celltrion In Deal With U.S.-based Hospira For Biogeneric Sales; M&A Hinted At

SEOUL - South Korea's Celltrion inked an agreement with U.S.-based Hospira to collaborate on manufacturing and marketing Celltrion's eight biogeneric products in global markets including the U.S. and Europe

South Korea's New Drug Pricing Policy Offers Incentives To Hospitals To Spend Less, Says Health Ministry

SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs plans to unveil on Oct. 31 its new drug reimbursement pricing system, which will lower profits for higher priced generics and still reward hospitals for buying drugs at lower prices

Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July

SEOUL - South Korea's FDA is putting the final touches on its EU-modeled initial guidelines for approval and registration of biosimilar products, and anticipates releasing a final version by the end of July

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel